At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
Rosuvastatin calciumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)
In Brief
A Phase 3 clinical trial evaluating Rosuvastatin calcium for Hypercholesteremia. Completed, across 57 sites in 8 countries.
Detailed Summary
The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesteremia
CountriesBelgium, Czechia, Finland, France, Germany, Netherlands, Norway, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2002
First PostedSep 2005
Primary CompletionMay 2006
TodayJul 2026
First PostedSep 26, 2005
Enrollment StartAug 1, 2002
Primary CompletionMay 1, 2006
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 20.8 years ago
Interventions
Rosuvastatin calciumdrug